Tg Therapeutics shares rise 8.36% intraday after completing $100M stock buyback and authorizing new $100M plan.

miércoles, 3 de septiembre de 2025, 10:37 am ET1 min de lectura
TGTX--
Tg Therapeutics, Inc. surged 8.36% intraday, after completing a $100 million share repurchase program and authorizing a new $100 million repurchase plan, demonstrating management's confidence in the company's outlook. The company is a commercial-stage biopharmaceutical company focused on developing therapies for B-cell diseases, with its flagship product, BRIUMVI, used to treat multiple sclerosis.

Tg Therapeutics shares rise 8.36% intraday after completing $100M stock buyback and authorizing new $100M plan.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios